The fusion of syngeneic DCs and tumor cells creates a heterokaryon with both tumor-derived antigens and DCs-derived MHC class II costimulatory molecules (B7.1 and B7.2), intracellular adhesion molecule- (ICAM-) 1, lymphocyte function-associated antigen- (LFA-) 1 and -3, and CD40, all of which are efficient antigen-processing and presentation machinery [15, 16]. Here, CD86 is linked to neoplasm.